Project Grant K23MH144148
Award Date 9/1/26
Completion Date 8/31/31
Dollars Obligated $199K
Federal Agency
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
La Jolla, CA 92093, USA
Similar Awards
- The National Institute of Mental Health awarded Vanderbilt University Medical Center $186,624 on May 1, 2026, under the Mental Health Research Grants program (CFDA 93.242, K23 award K23MH140069) to conduct a randomized clinical trial pilot study examining cognitive enhancement interventions for late-life depression with executive dysfunction. The study enrolls sixty non-demented older adults presenting with executive dysfunction and recurrent late-life depression in a four-week daily...
- The National Institute of Mental Health awarded The Leland Stanford Junior University $1,066,793 under the Mental Health Research Grants program (CFDA 93.242) on April 1, 2026, to develop and validate a personalized repetitive transcranial magnetic stimulation (rTMS) protocol for treatment-resistant depression using electrophysiological biomarkers. The award funds an R61/R33 phased study that will use early local TMS-evoked potentials (EL-TEPs)—measurements of prefrontal excitability—to...
- This federal Project Grant award of $498,429, provided by the National Institute of Mental Health (NIMH) under the Mental Health Research Grants program (CFDA 93.242), supports research to identify the key factors that determine an individual's response to transcranial direct current stimulation (tDCS). The research aims to apply machine learning algorithms to a large, multimodal dataset of over 225 tDCS-fMRI sessions to determine which factors, such as baseline task performance, brain...
- The National Institute of Mental Health awarded The McLean Hospital Corporation $771,937 on September 1, 2026, under the Mental Health Research Grants program (CFDA 93.242) to investigate the synaptic mechanisms underlying intermittent theta burst stimulation (ITBS) as a treatment for major depressive disorder. The research examines whether ITBS, an FDA-cleared patterned form of transcranial magnetic stimulation delivered clinically to the dorsolateral prefrontal cortex, works by enhancing...
- The National Institute of Mental Health awarded $1,488,310 to the University of North Carolina at Chapel Hill on August 1, 2026, under the Mental Health Research Grants program (CFDA 93.242) to evaluate personalized aperiodic transcranial alternating current stimulation as a treatment for antenatal depression. The research project, titled "Personalized Aperiodic Transcranial Alternating Current Stimulation as a Treatment for Antenatal Depression" (R61MH144538), develops and tests...
- The National Institute of Mental Health awarded Brigham & Women's Hospital Inc. $863,825 on August 1, 2026, under the Mental Health Research Grants program (CFDA 93.242) to conduct a double-blind, confirmatory efficacy trial comparing imaging-based targeting versus scalp-targeted accelerated transcranial magnetic stimulation (ATMS) for treatment-resistant major depressive disorder. The trial will enroll 120 participants to test whether imaging-targeted ATMS, using Stanford Accelerated...
- The National Institute of Mental Health awarded The Research Foundation for The State University of New York $437,125 on July 1, 2026, under the Mental Health Research Grants program (CFDA 93.242) to conduct a preliminary positron emission tomography study quantifying the mechanism of transcranial magnetic stimulation in depression. The recipient, operating as Stony Brook University, will investigate the relationship between repetitive transcranial magnetic stimulation (rTMS)—an FDA-approved...
- The National Institute of Mental Health awarded Trustees of Dartmouth College $114,152 on September 1, 2026, under the Mental Health Research Grants program (CFDA 93.242) to support research determining and enhancing the cellular selectivity of transcranial magnetic stimulation using optical physiology and computational models. The funded research directly tests predictions about how transcranial magnetic stimulation (TMS)—an FDA-approved treatment for drug-resistant depression,...
- The National Institute of Mental Health awarded Ampa Inc. $3.168 million on September 15, 2025, under the Mental Health Research Grants program (CFDA 93.242) to develop and validate a next-generation transcranial magnetic stimulation (TMS) system for scalable, personalized depression treatment. Ampa is engineering a portable TMS device that replicates the efficacy of Stanford Neuromodulation Therapy (SNT)—which achieves approximately 80 percent symptom remission in five treatment days—without...
- The National Institute of Mental Health awarded the University of New Mexico Health Sciences Center $194,779 on September 1, 2026, under the Mental Health Research Grants program (CFDA 93.242, K23 Career Development Award K23MH144291) to investigate brain excitability, seizure expression, and cognitive outcomes in electroconvulsive therapy for late-life depression. The research, titled CEASE-LD (Characterizing Brain Excitability, Adequacy of Seizures, and Efficacy in Late-Life Depression with...